Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 27

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Gender Related Changes in Gene Expression Induced by Valproic Acid in A Mouse Model of Autism and the Correction by S-adenosyl Methionine. Does It Explain the Gender Differences in Autistic Like Behavior?

Weinstein-Fudim, Liza, Ergaz, Zivanit, Turgeman, Gadi, Yanai, Joseph, Szyf, Moshe, Ornoy, Asher · 2019 · International Journal of Molecular Sciences

Abstract

In previous studies we produced autism like behavioral changes in mice by Valproic acid (VPA) with significant differences between genders. S-adenosine methionine (SAM) prevented the autism like behavior in both genders. The expression of 770 genes of pathways involved in neurophysiology and neuropathology was studied in the prefrontal cortex of 60 days old male and female mice using the NanoString nCounter. In females, VPA induced statistically significant changes in the expression of 146 genes; 71 genes were upregulated and 75 downregulated. In males, VPA changed the expression of only 19 genes, 16 were upregulated and 3 downregulated. Eight genes were similarly changed in both genders. When considering only the genes that were changed by at least 50%, VPA changed the expression of 15 genes in females and 3 in males. Only Nts was similarly downregulated in both genders. SAM normalized the expression of most changed genes in both genders. We presume that genes that are involved in autism like behavior in our model were similarly changed in both genders and corrected by SAM. The behavioral and other differences between genders may be related to genes that were differently affected by VPA in males and females and/or differently affected by SAM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms20215278

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Research works printed but not linked: 116

  1. Baio, 2018, Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years—Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2014, MMWR Surveill. Summ., 67, 1, 10.15585/mmwr.ss6706a1 · DOI · Paper page
  2. Lai, 2015, Sex/gender differences and autism: Setting the scene for future research, J. Am. Acad. Child Adolesc. Psychiatry, 54, 11, 10.1016/j.jaac.2014.10.003 · DOI · Paper page
  3. Beggiato, 2017, Gender differences in autism spectrum disorders: Divergence among specific core symptoms, Autism Res., 10, 680, 10.1002/aur.1715 · DOI · Paper page
  4. Rodier, 1996, Embryological origin for autism: Developmental anomalies of the cranial nerve motor nuclei, J. Comp. Neurol., 370, 247, 10.1002/(SICI)1096-9861(19960624)370:2<247::AID-CNE8>3.0.CO;2-2 · doi:10.1002/(sici)1096-9861(19960624)370:2<247::aid-cne8>3.0.co;2-2
  5. Silberstein, 2009, Preventive migraine treatment, Neurol. Clin., 27, 429, 10.1016/j.ncl.2008.11.007 · DOI · Paper page
  6. Post, 2011, Tolerance to the prophylactic effects of carbamazepine and related mood stabilizers in the treatment of bipolar disorders, CNS Neurosci., 17, 649, 10.1111/j.1755-5949.2010.00215.x · DOI
  7. Williams, 2001, Fetal valproate syndrome and autism: Additional evidence of an association, Dev. Med. Child Neurol., 43, 202, 10.1111/j.1469-8749.2001.tb00188.x · DOI · Paper page
  8. Wagner, 2006, A New Neurobehavioral Model of Autism in Mice: Pre- and Postnatal Exposure to Sodium Valproate, J. Autism Dev. Disord., 36, 779, 10.1007/s10803-006-0117-y · DOI · Paper page
  9. Rodrigues, 2011, Animal model of autism induced by prenatal exposure to valproate: Behavioral changes and liver parameters, Brain Res., 1408, 8, 10.1016/j.brainres.2011.06.015 · DOI · Paper page
  10. Kolozsi, 2009, Prenatal exposure to valproic acid leads to reduced expression of synaptic adhesion molecule neuroligin 3 in mice, Neuroscience, 163, 1201, 10.1016/j.neuroscience.2009.07.021 · DOI · Paper page
  11. Rodier, 1997, Linking etiologies in humans and animal models: Studies of autism, Reprod. Toxicol., 11, 417, 10.1016/S0890-6238(97)80001-U · DOI · Paper page
  12. Nicolini, 2018, The valproic acid-induced rodent model of autism, Exp. Neurol., 299, 217, 10.1016/j.expneurol.2017.04.017 · DOI · Paper page
  13. Jeon, 2018, Sex-specific Behavioral Features of Rodent Models of Autism Spectrum Disorder, Exp. Neurobiol., 27, 321, 10.5607/en.2018.27.5.321 · DOI · Paper page
  14. Ornoy, 2019, S-adenosyl methionine prevents ASD like behaviors triggered by early postnatal valproic acid exposure in very young mice, Neurotoxicol. Teratol., 71, 64, 10.1016/j.ntt.2018.01.005 · DOI · Paper page
  15. Schneider, 2008, Gender-specific behavioral and immunological alterations in an animal model of autism induced by prenatal exposure to valproic acid, Psychoneuroendocrinology, 33, 728, 10.1016/j.psyneuen.2008.02.011 · DOI · Paper page
  16. Kazlauskas, 2019, Sex-specific effects of prenatal valproic acid exposure on sociability and neuroinflammation: Relevance for susceptibility and resilience in autism, Psychoneuroendocrinology, 110, 104441, 10.1016/j.psyneuen.2019.104441 · DOI
  17. Sailer, 2019, Consequences of prenatal exposure to valproic acid in the socially monogamous prairie voles, Sci. Rep., 9, 2453, 10.1038/s41598-019-39014-7 · DOI
  18. Mabunga, 2015, Exploring the Validity of Valproic Acid Animal Model of Autism, Exp. Neurobiol., 24, 285, 10.5607/en.2015.24.4.285 · DOI · Paper page
  19. Choi, 2016, The transgenerational inheritance of autism-like phenotypes in mice exposed to valproic acid during pregnancy, Sci. Rep., 6, 36250, 10.1038/srep36250 · DOI
  20. Nowakowska, 2019, Genetics and epigenetics of autism spectrum disorder-current evidence in the field, J. Appl. Genet., 60, 37, 10.1007/s13353-018-00480-w · DOI · Paper page
  21. Lauber, 2016, Prenatal Valproate Exposure Differentially Affects Parvalbumin-Expressing Neurons and Related Circuits in the Cortex and Striatum of Mice, Front. Mol. Neurosci., 9, 150, 10.3389/fnmol.2016.00150 · DOI
  22. Hou, 2018, A Developmental Study of Abnormal Behaviors and Altered GABAergic Signaling in the VPA-Treated Rat Model of Autism, Front. Behav. Neurosci., 12, 182, 10.3389/fnbeh.2018.00182 · DOI
  23. Qin, 2016, Valproic acid exposure sequentially activates Wnt and mTOR pathways in rats, Mol. Cell. Neurosci., 75, 27, 10.1016/j.mcn.2016.06.004 · DOI
  24. Zhang, 2018, Transcriptional and splicing dysregulation in the prefrontal cortex in valproic acid rat model of autism, Reprod. Toxicol., 77, 53, 10.1016/j.reprotox.2018.01.008 · DOI
  25. Kobayashi, 2019, Effects of rapamycin on social interaction deficits and gene expression in mice exposed to valproic acid in utero, Mol. Brain, 12, 3, 10.1186/s13041-018-0423-2 · DOI
  26. Hill, 2015, Autism-Like Behavior and Epigenetic Changes Associated with Autism as Consequences of in UteroExposure to Environmental Pollutants in a Mouse Model, Behav. Neurol., 2015, 426263, 10.1155/2015/426263 · DOI
  27. Bezgin, 2018, Developmental changes of cortical white-gray contrast as predictors of autism diagnosis and severity, Transl. Psychiatry, 8, 249, 10.1038/s41398-018-0296-2 · DOI
  28. Wang, 2018, Decreased Number and Expression of nNOS-Positive Interneurons in Basolateral Amygdala in Two Mouse Models of Autism, Front. Cell. Neurosci., 12, 251, 10.3389/fncel.2018.00251 · DOI
  29. Rubio, 1989, Acute changes in 5-HT metabolism after S-adenosyl-L-methionine administration, Gen. Pharmacol. Vasc. Syst., 20, 403, 10.1016/0306-3623(89)90186-9 · DOI
  30. Villalobos, 2000, Effect of S-adenosyl-l-methionine on rat brain oxidative stress damage in a combined model of permanent focal ischemia and global ischemia-reperfusion, Brain Res., 883, 31, 10.1016/S0006-8993(00)02873-0 · DOI
  31. Ortiz, 1997, Effects ofS-adenosyl-L-methionine on hepatic and renal oxidative stress in an experimental model of acute biliary obstruction in rats, Hepatology, 26, 121
  32. Li, 2017, S-Adenosylmethionine Attenuates Oxidative Stress and Neuroinflammation Induced by Amyloid-beta Through Modulation of Glutathione Metabolism, J. Alzheimers Dis., 58, 549, 10.3233/JAD-170177 · DOI
  33. Yoon, 2016, S-adenosylmethionine reduces airway inflammation and fibrosis in a murine model of chronic severe asthma via suppression of oxidative stress, Exp. Mol. Med., 48, e236, 10.1038/emm.2016.35 · DOI
  34. Morrison, 1996, Brain S-adenosylmethionine levels are severely decreased in Alzheimer’s disease, J. Neurochem., 67, 1328, 10.1046/j.1471-4159.1996.67031328.x · DOI · Paper page
  35. Mischoulon, 2014, A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder, J. Clin. Psychiatry, 75, 370, 10.4088/JCP.13m08591 · DOI
  36. Williams, 2005, S-adenosylmethionine (SAMe) as treatment for depression: A systematic review, Clin. Investig. Med., 28, 132
  37. Sharma, 2017, S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research, J. Clin. Psychiatry, 78, e656, 10.4088/JCP.16r11113 · DOI
  38. Sarris, 2015, Is S-Adenosyl Methionine (SAMe) for Depression Only Effective in Males? A Re-Analysis of Data from a Randomized Clinical Trial, Pharmacopsychiatry, 48, 141, 10.1055/s-0035-1549928 · DOI
  39. Ding, W., Higgins, D.P., Yadav, D.K., Godbole, A.A., Pukkila-Worley, R., and Walker, A.K. (2018). Stress-responsive and metabolic gene regulation are altered in low S-adenosylmethionine. PLoS Genet., 14. · doi:10.1101/346205
  40. Cho, 2017, Changes in brain metabolic connectivity underlie autistic-like social deficits in a rat model of autism spectrum disorder, Sci. Rep., 7, 13213, 10.1038/s41598-017-13642-3 · DOI
  41. Kim, 2017, Sex Differences in Autism-Like Behavioral Phenotypes and Postsynaptic Receptors Expression in the Prefrontal Cortex of TERT Transgenic Mice, Biomol. Ther., 25, 374, 10.4062/biomolther.2016.242 · DOI
  42. Nway, 2018, Social behavior, neuroimmune markers and glutamic acid decarboxylase levels in a rat model of valproic acid-induced autism, J. Toxicol. Sci., 43, 631, 10.2131/jts.43.631 · DOI
  43. Smith, 2012, NTS1 and NTS2 mediate analgesia following neurotensin analog treatment in a mouse model for visceral pain, Behav. Brain Res., 232, 93, 10.1016/j.bbr.2012.03.044 · doi:10.1016/j.bbr.2012.03.044
  44. Merullo, 2015, Neurotensin neural mRNA expression correlates with vocal communication and other highly-motivated social behaviors in male European starlings, Physiol. Behav., 151, 155, 10.1016/j.physbeh.2015.07.019 · DOI
  45. Gammie, 2009, Neurotensin inversely modulates maternal aggression, Neuroscience, 158, 1215, 10.1016/j.neuroscience.2008.11.045 · DOI
  46. Fitzpatrick, 2012, Altered Sleep and Affect in the Neurotensin Receptor 1 Knockout Mouse, Sleep, 35, 949, 10.5665/sleep.1958 · DOI
  47. Levitas-Djerbi, T., Sagi, D., Lebenthal-Loinger, I., Lerer-Goldshtein, T., and Appelbaum, L. (2019). Neurotensin Enhances Locomotor Activity and Arousal, and Inhibits Melanin-Concentrating Hormone Signalings. Neuroendocrinology, in press. · DOI
  48. Kinkead, 2006, Neurotensin: Role in psychiatric and neurological diseases, Peptides, 27, 2385, 10.1016/j.peptides.2006.04.024 · DOI
  49. Shilling, 2008, The neurotensin-1 receptor agonist PD149163 blocks fear-potentiated startle, Pharmacol. Biochem. Behav., 90, 748, 10.1016/j.pbb.2008.05.025 · DOI
  50. Cervo, 1992, Antidepressant-like effect of neurotensin administered in the ventral tegmental area in the forced swimming test, Psychopharmacology, 109, 369, 10.1007/BF02245885 · DOI
  51. Binder, 2001, Neurotensin and dopamine interactions, Pharmacol. Rev., 53, 453
  52. Dobner, 2005, Multitasking with neurotensin in the central nervous system, Cell. Mol. Life Sci., 62, 1946, 10.1007/s00018-005-5128-x · DOI
  53. Yin, 2008, Neurotensin reduces glutamatergic transmission in the dorsolateral striatum via retrograde endocannabinoid signaling, Neuropharmacology, 54, 79, 10.1016/j.neuropharm.2007.06.004 · DOI
  54. Kadiri, 2011, Neurotensin inhibits background K+ channels and facilitates glutamatergic transmission in rat spinal cord dorsal horn, Eur. J. Neurosci., 34, 1230, 10.1111/j.1460-9568.2011.07846.x · DOI
  55. Ferraro, 2008, Neurotensin receptors as modulators of glutamatergic transmission, Brain Res. Rev., 58, 365, 10.1016/j.brainresrev.2007.11.001 · DOI
  56. Rakovska, 1998, Neurotensin modulation of acetylcholine and gaba release from the rat hippocampus: An in vivo microdialysis study, Neurochem. Int., 33, 335, 10.1016/S0197-0186(98)00036-9 · doi:10.1016/s0197-0186(98)00036-9
  57. Rakovska, 2008, Neurotensin modulation of acetylcholine, GABA, and aspartate release from rat prefrontal cortex studied in vivo with microdialysis, Brain Res. Bull., 77, 129, 10.1016/j.brainresbull.2008.04.003 · DOI
  58. Petrie, 2005, Neurotensin Activates GABAergic Interneurons in the Prefrontal Cortex, J. Neurosci., 25, 1629, 10.1523/JNEUROSCI.3579-04.2005 · DOI
  59. Vincent, 1999, Neurotensin and neurotensin receptors, Trends Pharmacol. Sci., 20, 302, 10.1016/S0165-6147(99)01357-7 · DOI · Paper page
  60. Martin, 2003, Involvement of the Neurotensin Receptor-3 in the Neurotensin-Induced Migration of Human Microglia, J. Neurosci., 23, 1198, 10.1523/JNEUROSCI.23-04-01198.2003 · DOI
  61. Vadnie, 2014, Activation of neurotensin receptor type 1 attenuates locomotor activity, Neuropharmacology, 85, 482, 10.1016/j.neuropharm.2014.05.046 · DOI
  62. Keiser, 2014, Systemic administration of the neurotensin NTS-receptor agonist PD149163 improves performance on a memory task in naturally deficient male brown Norway rats, Exp. Clin. Psychopharmacol., 22, 541, 10.1037/a0037912 · DOI
  63. Angelidou, 2010, Neurotensin is increased in serum of young children with autistic disorder, J. Neuroinflamm., 7, 48, 10.1186/1742-2094-7-48 · DOI
  64. Tsilioni, 2014, Elevated serum neurotensin and CRH levels in children with autistic spectrum disorders and tail-chasing Bull Terriers with a phenotype similar to autism, Transl. Psychiatry, 4, e466, 10.1038/tp.2014.106 · DOI
  65. Patel, 2016, Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism, Proc. Natl. Acad. Sci. USA, 113, E7049, 10.1073/pnas.1604992113 · DOI
  66. Ghanizadeh, 2010, Targeting neurotensin as a potential novel approach for the treatment of autism, J. Neuroinflamm., 7, 58, 10.1186/1742-2094-7-58 · DOI
  67. Kirsten, T.B., Casarin, R.C., Bernardi, M.M., and Felicio, L.F. (2018). Pioglitazone abolishes autistic-like behaviors via the IL-6 pathway. PLoS ONE, 13. · DOI
  68. Kirsten, 2019, Pioglitazone abolishes cognition impairments as well as BDNF and neurotensin disturbances in a rat model of autism, Biol. Open, 8, bio041327, 10.1242/bio.041327 · DOI
  69. Normandeau, 2018, A Key Role for Neurotensin in Chronic-Stress-Induced Anxiety-Like Behavior in Rats, Neuropsychopharmacology, 43, 285, 10.1038/npp.2017.134 · DOI
  70. Lipstein, 2017, Synaptic UNC13A protein variant causes increased neurotransmission and dyskinetic movement disorder, J. Clin. Investig., 127, 1005, 10.1172/JCI90259 · DOI
  71. Damaj, 2015, CACNA1A haploinsufficiency causes cognitive impairment, autism and epileptic encephalopathy with mild cerebellar symptoms, Eur. J. Hum. Genet., 23, 1505, 10.1038/ejhg.2015.21 · DOI · Paper page
  72. Lee, 2012, Multi-locus genome-wide association analysis supports the role of glutamatergic synaptic transmission in the etiology of major depressive disorder, Transl. Psychiatry, 2, e184, 10.1038/tp.2012.95 · DOI
  73. Horder, 2013, Reduced subcortical glutamate/glutamine in adults with autism spectrum disorders: A [H] MRS study, Transl. Psychiatry, 3, e279, 10.1038/tp.2013.53 · DOI
  74. Bernardi, 2011, In vivo 1H-magnetic resonance spectroscopy study of the attentional networks in autism, Brain Res., 1380, 198, 10.1016/j.brainres.2010.12.057 · DOI
  75. Page, 2006, In Vivo 1 H-Magnetic Resonance Spectroscopy Study of Amygdala-Hippocampal and Parietal Regions in Autism, Am. J. Psychiatry, 163, 2189, 10.1176/ajp.2006.163.12.2189 · doi:10.1176/ajp.2006.163.12.2189
  76. Wickens, 2018, Sex Differences in Psychiatric Disease: A Focus on the Glutamate System, Front. Mol. Neurosci., 11, 197, 10.3389/fnmol.2018.00197 · DOI
  77. Gustavsson, 2014, Dopamine D1 receptor availability is related to social behavior: A positron emission tomography study, NeuroImage, 102, 590, 10.1016/j.neuroimage.2014.08.018 · DOI
  78. Homberg, 2016, The role of the dopamine D1 receptor in social cognition: Studies using a novel genetic rat model, Dis. Model. Mech., 9, 1147
  79. Canals, 2003, Adenosine A2A-dopamine D2 receptor-receptor heteromerization: Qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer, J. Biol. Chem., 278, 46741, 10.1074/jbc.M306451200 · DOI · Paper page
  80. Collins, 2014, Opponent actor learning (OpAL): Modeling interactive effects of striatal dopamine on reinforcement learning and choice incentive, Psychol. Rev., 121, 337, 10.1037/a0037015 · DOI · Paper page
  81. Vorstman, 2006, The 22q11.2 deletion in children: High rate of autistic disorders and early onset of psychotic symptoms, J. Am. Acad. Child Adolesc. Psychiatry, 45, 1104, 10.1097/01.chi.0000228131.56956.c1 · DOI · Paper page
  82. Deckert, 1996, Human adenosine A2a receptor (A2aAR) gene: Systematic mutation screening in patients with schizophrenia, J. Neural Transm., 103, 1447, 10.1007/BF01271259 · DOI
  83. Hong, 2005, Association studies of the adenosine A2a receptor (1976T > C) genetic polymorphism in Parkinson’s disease and schizophrenia, J. Neural Transm., 112, 1503, 10.1007/s00702-005-0286-4 · DOI
  84. Hohoff, 2010, Adenosine A2A receptor gene: Evidence for association of risk variants with panic disorder and anxious personality, J. Psychiatr. Res., 44, 930, 10.1016/j.jpsychires.2010.02.006 · DOI
  85. Freitag, 2010, Adenosine A (2A) receptor gene (ADORA2A) variants may increase autistic symptoms and anxiety in autism spectrum disorder, Eur. Child Adolesc. Psychiatry, 19, 67, 10.1007/s00787-009-0043-6 · DOI
  86. Squillace, 2014, Dysfunctional dopaminergic neurotransmission in asocial BTBR mice, Transl. Psychiatry, 4, e427, 10.1038/tp.2014.69 · DOI
  87. Traynelis, 2010, Glutamate receptor ion channels: Structure, regulation, and function, Pharmacol. Rev., 62, 405, 10.1124/pr.109.002451 · DOI · Paper page
  88. Chen, 2017, Next-generation DNA sequencing identifies novel gene variants and pathways involved in specific language impairment, Sci. Rep., 7, 46105, 10.1038/srep46105 · DOI
  89. Gao, K., Tankovic, A., Zhang, Y., Kusumoto, H., Zhang, J., Chen, W., Xiangwei, W., Shaulsky, G.H., Hu, C., and Traynelis, S.F. (2017). A de novo loss-of-function GRIN2A mutation associated with childhood focal epilepsy and acquired epileptic aphasia. PLoS ONE, 12. · DOI
  90. Goswami, 2013, Gene expression analysis of novel genes in the prefrontal cortex of major depressive disorder subjects, Prog. Neuropsychopharmacol. Biol. Psychiatry, 43, 126, 10.1016/j.pnpbp.2012.12.010 · DOI
  91. Lee, 2011, Flt-1 regulates vascular endothelial cell migration via a protein tyrosine kinase-7–dependent pathway, Blood, 117, 5762, 10.1182/blood-2010-09-306928 · DOI
  92. Shibuya, 2006, Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis, J. Biochem. Mol. Biol., 39, 469
  93. Mahoney, E.R., Dumitrescu, L., Moore, A.M., Cambronero, F.E., De Jager, P.L., Koran, M.E.I., Petyuk, V.A., Robinson, R.A.S., Goyal, S., and Schneider, J.A. (2019). Brain expression of the vascular endothelial growth factor gene family in cognitive aging and alzheimer’s disease. Mol. Psychiatry, in press. · DOI · Paper page
  94. Hu, V.W., Frank, B.C., Heine, S., Lee, N.H., and Quackenbush, J. (2006). Gene expression profiling of lymphoblastoid cell lines from monozygotic twins discordant in severity of autism reveals differential regulation of neurologically relevant genes. BMC Genom., 7. · DOI · Paper page
  95. Maurer, 2017, The Cholinergic System Modulates Memory and Hippocampal Plasticity via Its Interactions with Non-Neuronal Cells, Front. Immunol., 8, 1489, 10.3389/fimmu.2017.01489 · DOI · Paper page
  96. Ballinger, 2016, Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline, Neuron, 91, 1199, 10.1016/j.neuron.2016.09.006 · DOI · Paper page
  97. Sarter, 2012, Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatments, Neuropharmacology, 62, 1544, 10.1016/j.neuropharm.2010.12.001 · DOI
  98. Hardan, 2002, A Retrospective Open Trial of Adjunctive Donepezil in Children and Adolescents with Autistic Disorder, J. Child Adolesc. Psychopharmacol., 12, 237, 10.1089/104454602760386923 · DOI
  99. Wang, 2015, Modulation of social deficits and repetitive behaviors in a mouse model of autism: The role of the nicotinic cholinergic system, Psychopharmacology, 232, 4303, 10.1007/s00213-015-4058-z · DOI
  100. Perry, 2001, Cholinergic Activity in Autism: Abnormalities in the Cerebral Cortex and Basal Forebrain, Am. J. Psychiatry, 158, 1058, 10.1176/appi.ajp.158.7.1058 · DOI · Paper page
  101. Han, 2017, Author Correction: Down-regulation of cholinergic signaling in the habenula induces anhedonia-like behavior, Sci. Rep., 7, 17090, 10.1038/s41598-017-16991-1 · doi:10.1038/s41598-017-16991-1
  102. Bierer, 1995, Neurochemical correlates of dementia severity in Alzheimer’s disease: Relative importance of the cholinergic deficits, J. Neurochem., 64, 749, 10.1046/j.1471-4159.1995.64020749.x · DOI · Paper page
  103. Giannini, 1995, The ryanodine receptor/calcium channel genes are widely and differentially expressed in murine brain and peripheral tissues, J. Cell Boil., 128, 893, 10.1083/jcb.128.5.893 · DOI · Paper page
  104. Galeotti, 2008, Different involvement of type 1, 2, and 3 ryanodine receptors in memory processes, Learn. Mem., 15, 315, 10.1101/lm.929008 · DOI
  105. Pratt, 2015, Critical Role of Intracellular RyR1 Calcium Release Channels in Skeletal Muscle Function and Disease, Front. Physiol., 6, 420
  106. Kulkarni, M.M. (2011). Digital multiplexed gene expression analysis using the NanoString nCounter system. Curr. Protoc. Mol. Biol. · DOI · Paper page
  107. Sherman, 2009, Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists, Nucleic Acids Res., 37, 1, 10.1093/nar/gkn923 · DOI · Paper page
  108. Salman, 2017, Transcriptome analysis suggests a role for the differential expression of cerebral aquaporins and the MAPK signalling pathway in human temporal lobe epilepsy, Eur. J. Neurosci., 46, 2121, 10.1111/ejn.13652 · DOI
  109. Salman, 2017, Transcriptome Analysis of Gene Expression Provides New Insights into the Effect of Mild Therapeutic Hypothermia on Primary Human Cortical Astrocytes Cultured under Hypoxia, Front. Cell. Neurosci., 11, 386, 10.3389/fncel.2017.00386 · DOI
  110. Kim, 2015, The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer, Clin. Transl. Oncol., 17, 462, 10.1007/s12094-014-1258-7 · DOI
  111. Leal, 2018, Reproducibility of the NanoString 22-gene molecular subgroup assay for improved prognostic prediction of medulloblastoma, Neuropathology, 38, 475, 10.1111/neup.12508 · DOI
  112. Trubicka, 2018, Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis, J. Neuro-Oncol., 138, 231, 10.1007/s11060-018-2797-5 · doi:10.1007/s11060-018-2797-5
  113. Zapka, 2018, Type, Frequency, and Spatial Distribution of Immune Cell Infiltrates in CNS Germinomas: Evidence for Inflammatory and Immunosuppressive Mechanisms, J. Neuropathol. Exp. Neurol., 77, 119, 10.1093/jnen/nlx106 · DOI
  114. Solomon, I.H., De Girolami, U., Chettimada, S., Misra, V., Singer, E.J., and Gabuzda, D. (2017). Brain and liver pathology, amyloid deposition, and interferon responses among older HIV-positive patients in the late HAART era. BMC Infect. Dis., 17. · DOI
  115. Prokopec, 2013, Systematic evaluation of medium-throughput mRNA abundance platforms, RNA, 19, 51, 10.1261/rna.034710.112 · DOI
  116. Oldridge, 1990, The health belief model: Predicting compliance and dropout in cardiac rehabilitation, Med. Sci. Sports Exerc., 22, 678, 10.1249/00005768-199010000-00020 · DOI

Cited by

See all 27

Metadata

Authors
Weinstein-Fudim, L., Ergaz, Z., Turgeman, G., Yanai, J., Szyf, M., & Ornoy, A.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2019-10-24
Volume
20
Issue
21
Pages
5278
ISSN
1422-0067
Cited by
27
References
15
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.